Metabasis Therapeutics Inc.
11119 North Torrey Pines Road
La Jolla,
CA 92037
United States - Map
Phone: 858-587-2770
Fax: 858-458-3504
Web Site: http://www.mbasis.com
| Metabasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel drugs for targeting the liver and liver pathways. Its pipeline includes product candidates and advanced research programs for treating metabolic diseases, such as diabetes and hyperlipidemia. The company’s product portfolio comprises MB07803, a Phase IIa product candidate for treating type II diabetes; and MB07811, a Phase 1 product candidate for hyperlipidemia. Metabasis also develops pradefovir and MB07133, which are in clinical stage of development for the treatment of hepatitis B viral disease and primary liver cancer. It has a collaboration with Merck & Co., Inc. to develop AMPK activators for diabetes and other metabolic diseases. The company was founded in 1997 and is based in La Jolla, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Paul Laikind Ph.D., 52
Co-Founder, Chief Exec. Officer, Pres, Interim Chief Financial Officer, Sec. |
N/A
| N/A | Dr. Mark D. Erion Ph.D., 50
Co-Founder, Chief Scientific Officer, Exec. VP of R&D |
N/A
| N/A | Dr. Edgardo Baracchini Ph.D., MBA, 48
Sr. VP of Bus. Devel. |
N/A
| N/A | Dr. Howard Foyt M.D., Ph.D., 54
VP of Clinical Devel. |
N/A
| N/A | Ms. Trisha Millican , 35
Interim Principal Accounting Officer and Corp. Controller |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
6.54% Nasdaq 
Profile
